Sutro Biopharma Inc. (STRO): Analysis on the Earning Per Share


Sutro Biopharma Inc. (NASDAQ:STRO) changes shares on Friday trading session, with a change of -13.60% or -$1.14 shares. The trading starts at $8.38 and closed at $8.38 throughout the day. The trading session low price was $7.06 and day high was $8.3919 on Friday, June 26. After the session, the Healthcare sector daily volume shifted to 0.99 million while its average volume is 109.75K. In other hand, the STRO market cap reached to $266.29M. While, its current target price is $7.24 according to WSJ.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -21.81% and down -24.58% for month. Its quarterly performance was -26.05% below, while its half year performance is down -33.70%. STRO yearly performance stood at negative -36.16% and fall -34.18% for year-to-date. Current recommendation for Sutro Biopharma Inc. is 1.70.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. STRO EPS (TTM) for 12-month is -2.65. EPS for this year is -57.10%, while for the next year its value is -2.58. Its EPS Q/Q reached -35.50%.

Let’s take a look on the analyst recommendations on STRO for the current month and previous month. For the current month, 7 of 7 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $16.00-$20.00. Average target price for STRO was reached at $18.50.

Sv Health Investors, LLC, Citadel Advisors LLC and Eventide Asset Management LLC are the top three holders in Sutro Biopharma Inc. (STRO) stock. On Mar 30, 2020, Sv Health Investors, LLC has 1.82 million shares which valued 18.61 million. On Mar 30, 2020, Citadel Advisors LLC owned 1.55 million shares which valued at 15.8 million. On Mar 30, 2020, Eventide Asset Management LLC has a total of 1.29 million shares which valued at 13.12 million. In the end, Eventide Asset Management LLC have 5.54% shares outstanding of Sutro Biopharma Inc. (STRO) on Mar 30, 2020. The insider ownership moved to 0.60% and institutional holding shifted to 49.10%.

The company posted an EPS (TTM) of -2.65. According to the most recent quarter report on (Jun 2020), 7 analysts estimated an average EPS of -0.63, while -0.6 EPS posted a year ago period. Analyst Estimated EPS for STRO published in the report was -0.85–0.47 during the same period. Comparing with last year, the average estimated EPS was -0.6 which is higher than -0.84 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for STRO fall -28.91% for period of 200 days. SMA for 50 days was -25.11% which is showing red signal, while SMA-20 was -23.91%. The moving average value for Sutro Biopharma Inc. (STRO) is 10.17 and 9.44 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in STRO stock. On May 26, Hallam Trevor, Chief Science Officer, sold 975 trading shares at the cost of $10.00, which valued at 9753.0. On May 14, NEWELL WILLIAM J, CEO, bought 64,516 shares at the cost of $7.75, with total shares of 166,627. On May 14, MOLINA ARTURO MD, Chief Medical Officer, bought 6,451 shares at the cost of 7.75. After this transaction, MOLINA ARTURO MD total shares reached to 12,083 which valued at 49995.0.